SILVIA MARIA DÍAZ PRADO | Drug Delivery Systems | Lifetime achievement Award

Published on by Top Pharmaceutical

SILVIA MARIA DÍAZ PRADO | Drug Delivery Systems | Lifetime achievement Award

Prof. Dr. SILVIA MARIA DÍAZ PRADO, University of A Coruña, Spain

Prof. Dr. Silvia María Díaz Prado is a Professor of Anatomy at the University of A Coruña and leads the Cellular Therapy and Regenerative Medicine Group at INIBIC. With a PhD in Biology (2004), her research spans tissue engineering, stem cells 🧬 (including iPSCs), novel biomaterials, 3D bioprinting 🖨️, and nanoparticle drug delivery 💊. She has published 68 articles (H-index: 24), 32 book chapters, and presented at 215 conferences. Dr. Díaz Prado has led 33 research projects, supervised over 50 theses, and received 7 research awards 🏅. She coordinates the Master’s in Health Care and Research program.

Publication Profile

Google Scholar

Education

Prof. Dr. Silvia María Díaz Prado 🎓 holds a Ph.D. in Biology (2004) from the University of A Coruña, where she serves as a Professor of Anatomy 🧠 and coordinates the Master’s Degree in Health Care and Research 💉📚. With a distinguished academic career, she has played a pivotal role in shaping advanced medical education and fostering scientific inquiry 🔬. Her dedication to teaching and mentorship has inspired countless students and researchers, reinforcing her status as a respected leader in the biomedical field 🌟. Prof. Dr. Díaz Prado continues to advance excellence in health sciences through education and innovation.

Awards

Prof. Dr. Silvia María Díaz Prado 🏅 has been honored with seven prestigious research awards 🧪, reflecting the high regard in which her scientific contributions are held by the academic community 🌍. These accolades underscore her exceptional merit, dedication to innovation, and impactful work in the field of biomedical research 🧬. Each award stands as a testament to her relentless pursuit of knowledge, excellence, and advancement in science 🔍✨. Prof. Díaz Prado’s achievements not only bring recognition to her individual efforts but also elevate the institutions and research teams she represents, inspiring future generations of scientists 🎓🌟.

Research Focus

Prof. Dr. Silvia María Díaz-Prado is a distinguished researcher in the field of Regenerative Medicine 🧬🦴, with a strong focus on stem cells, cartilage repair, and molecular signaling in musculoskeletal disorders. Her groundbreaking work explores microRNA profiling🧪, mesenchymal stem cells🧫, and the human amniotic membrane as a novel source for cell therapy. She also investigates oncogenic pathways like Wnt, Notch, and Hedgehog 🔬, linking them to cancer stem cells. Prof. Díaz-Prado’s contributions bridge molecular biology with clinical applications, making her a key figure in orthopedic tissue engineering, biomarkers, and cell-based therapeutic strategies.

Publication Top Notes

Characterization of microRNA expression profiles in normal and osteoarthritic human chondrocytes

Cloning genes from a library using a clustering strategy and PCR

Multilineage differentiation potential of cells isolated from the human amniotic membrane

Human amniotic membrane as an alternative source of stem cells for regenerative medicine

Wnt signalling and cancer stem cells

Notch signalling in cancer stem cells

Potential use of the human amniotic membrane as a scaffold in human articular cartilage repair

Quantification of cells expressing mesenchymal stem cell markers in healthy and osteoarthritic synovial membranes

Effects of severe hypoxia on bone marrow mesenchymal stem cells differentiation potential

Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer

Isolation and characterization of mesenchymal stem cells from human amniotic membrane

Induced pluripotent stem cells for cartilage repair: current status and future perspectives

Biology of BMP signalling and cancer

Oliwia Kordyl | Drug Delivery Systems | Best Research Article Award

Published on by Top Pharmaceutical

Oliwia Kordyl | Drug Delivery Systems | Best Research Article Award

Ms. Oliwia Kordyl, Poznan Univeristy of Medical Sciences, Poland

Ms. Oliwia Kordyl (b. June 9, 1997) is a dedicated PhD student at Poznan University of Medical Sciences, specializing in 3D printed microneedles for targeted drug delivery. With a background in biotechnology from Adam Mickiewicz University, her work spans molecular biology, pharmaceutical technology, and reproductive genetics. Oliwia has held roles as a lab manager, molecular biologist, and biotechnologist, contributing to innovative projects and scientific conferences. She is skilled in advanced lab techniques and passionate about travel, fitness, and continuous learning.

Publication Profile

orcid

Education

Ms. Oliwia Kordyl is currently pursuing her Ph.D. (Nov 2023–Present) at the Poznan University of Medical Sciences in Poland, focusing on 3D printed microneedles for voriconazole delivery in treating local skin infections. Her research involves optimizing microneedle manufacturing, assessing physicochemical and pharmaceutical properties in vitro, and evaluating drug permeation ex vivo and microbiological effectiveness 🧪🧬. She earned her M.Sc. and B.Sc. in biotechnology from Adam Mickiewicz University (2016–2021), where she explored DNA methylation in oligozoospermia and gene expression in spermatogenesis 🧫. Her academic journey began at K.K. Baczyński Secondary School, specializing in biology, physics, and chemistry 🔬📚.

Experience

Ms. Oliwia Kordyl completed a valuable internship at Novazym Polska in Poznań from July to August 2019. During her time at this renowned biotechnology company, she gained hands-on experience in laboratory techniques and deepened her understanding of industrial biotechnology practices 🔬💼. The internship provided her with practical insights into the daily operations of a biotech firm and allowed her to apply her academic knowledge in a real-world setting 🧪📊. This experience not only enhanced her technical skills but also strengthened her passion for research and innovation in the field of biotechnology, laying a strong foundation for her future scientific endeavors 🚀.

Awards

🏆 Ms. Oliwia Kordyl has actively contributed to the scientific community through speeches and posters at esteemed conferences. She presented on sperm DNA methylation at the 21st Andrology Day (2019) 🧬 and the 21st European Testis Workshop (2021) in Barcelona. Her posters featured at ESHRE 2020, the European Human Genetics Conference (2021), and the 6th Polish Congress of Genetics (2022) showcased her expertise in epigenetics and sperm chromatin structure 🧫📊. In 2023, she co-authored a poster on microneedles for transdermal drug delivery at PolGerSym10 💉. Oliwia also co-authored a publication in the International Journal of Molecular Sciences (2022) 📄📚.

Research Focus

Ms. Oliwia Kordyl’s research focuses on the development of innovative drug delivery systems, particularly microneedle-based technologies for transdermal applications. Her work combines 3D printing, pharmaceutical coatings, and hydrogel systems to enhance the treatment of bacterial and fungal skin infections. She also explores photodynamic therapy and nanotechnology for targeted drug release. Her interdisciplinary approach bridges materials science, biomedical engineering, and pharmaceutics. Additionally, her research extends to epigenetic analysis in human sperm, highlighting her interest in reproductive biology. Her work is at the frontier of personalized medicine, non-invasive therapies, and advanced pharmaceutical technologies.

Publication Top Notes

Optimization of LCD-Based 3D Printing for the Development of Clotrimazole-Coated Microneedle Systems

Microneedle-based arrays – Breakthrough strategy for the treatment of bacterial and fungal skin infections

Microneedle System Coated with Hydrogels Containing Protoporphyrin IX for Potential Application in Pharmaceutical Technology

Global 5mC and 5hmC DNA Levels in Human Sperm Subpopulations with Differentially Protaminated Chromatin in Normo- and Oligoasthenozoospermic Males

YORINOBU MAEDA | Drug Delivery Systems | Pharmaceutical Advancement Award

Published on by Top Pharmaceutical

YORINOBU MAEDA | Drug Delivery Systems | Pharmaceutical Advancement Award

Prof Dr YORINOBU MAEDA, Fukuyama university, Japan

Prof. Dr. Yorinobu Maeda, Ph.D. (Hiroshima University, 1990), is a renowned expert in drug safety, pharmacokinetics, and infection control. As a professor at Fukuyama University and Drug Safety Director, he has advanced renal function-based dosing and prescription optimization. His contributions have earned him multiple awards, including Best Paper Awards (2001, 2005) and an Academic Contribution Award (2014) from the Japanese Society of Pharmaceutical Health Care and Sciences. With a strong academic and clinical impact, Dr. Maeda is a leading figure in pharmaceutical advancements, ensuring better patient safety and treatment efficacy. 🏅🔬

Publication Profile

scopus

Educational and Professional Background

Prof. Dr. Yorinobu Maeda has a distinguished background in pharmaceutical sciences, earning his Ph.D. from Hiroshima University in 1990 🎓. His expertise spans infection control, hospital pharmacy specialization, and drug safety leadership, reflecting his dedication to pharmaceutical advancements 💊. With leadership roles in major hospitals 🏥 and an esteemed position as a professor at Fukuyama University 🎓, he has made significant academic and practical contributions to the field. His work continues to shape the future of pharmacy, ensuring patient safety and advancing healthcare practices for better medical outcomes 🌍🔬.

Contributions to Pharmaceutical Sciences

Prof. Dr. Yorinobu Maeda has made significant contributions to pharmaceutical sciences, particularly in drug safety, pharmacokinetics, and dosage optimization 💊🔬. His research focuses on infection control 🦠, renal function-based dosing 🏥, and improving prescription practices, directly enhancing patient safety and treatment efficacy 👨‍⚕️✅. As a Drug Safety Director, he plays a crucial role in advancing pharmaceutical practices, ensuring medications are used effectively and safely. His dedication to optimizing drug therapy and refining medical protocols continues to have a lasting impact on healthcare, improving outcomes for patients worldwide 🌍💉.

Awards and Recognitions

Prof. Dr. Yorinobu Maeda has made remarkable contributions to the field of pharmaceutical healthcare, earning numerous prestigious accolades from the Japanese Society of Pharmaceutical Health Care and Sciences. His achievements include the Best Paper Awards in 2001 and 2005 🏆, as well as the esteemed Academic Contribution Award in 2014 🎓. These honors highlight his dedication to advancing research and implementing pharmacokinetic principles to enhance patient safety and care 🩺. Dr. Maeda’s work stands as a testament to his unwavering commitment to improving healthcare standards and fostering innovation in pharmaceutical sciences. 🌟

Research Focus

Professor Dr. Yorinobu Maeda is an eminent researcher specializing in pharmaceutical sciences, with a primary focus on drug bioavailability, prodrug development, and therapeutic drug monitoring. His work spans areas such as drug absorption, small intestinal bacterial overgrowth diagnosis, and managing adverse drug reactions. Notable research includes the impact of metal ions on drug efficacy and innovative prodrug strategies. Through collaborative studies, he contributes to optimizing drug delivery systems and clinical pharmacotherapy, enhancing patient safety and treatment outcomes. 🧪💊

Publication Top Notes

5-Aminosalicylic Acid Distribution into the Intestinal Membrane Along the Gastrointestinal Tract After Oral Administration in Rats

Development and Evaluation of EDTA-Treated Rabbits for Bioavailability Study of Chelating Drugs Using Levofloxacin, Ciprofloxacin, Hemiacetal Ester Prodrugs, and Tetracycline

Diagnosis by Microbial Culture, Breath Tests and Urinary Excretion Tests, and Treatments of Small Intestinal Bacterial Overgrowth

Ester Prodrugs of Levofloxacin to Prevent Chelate Formation in Presence of Aluminium Ion

Study on the method to avoid infusion‑site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells

Effect of aluminium ion on bioavailability of levofloxacin following oral administration of cilexetil ester of levofloxacin as prodrug in rats

 Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant

Dosage adjustment of dabigatran etexilate based on creatinine clearance in patients with cardioembolic stroke or atrial fibrillation

Interaction of magnesium oxide with gastric acid secretion inhibitors in clinical pharmacotherapy

 

Prof.Aleksandr Urakov|Drug Repurposing | Best Researcher Award

Published on by Top Pharmaceutical

Prof.Aleksandr Urakov, Drug Repurposing ,Best Researcher Award

Prof.Aleksandr Urakov atIzhevsk State Medical Academy,Russia

PROFILE  

scopus

Orcid

Academic Leadership 🏫

Professor Aleksandr Urakov serves as the head of the Department of General and Clinical Pharmacology at Izhevsk State Medical Academy. His leadership has been instrumental in shaping the department into a center of excellence in pharmacological research and education.

Innovative Contributions 🧠

As an inventor, Professor Urakov holds over 270 patents and has published more than 200 scientific articles . His research in temperature pharmacology and drug repurposing  has led to significant advancements, including the development of the floating tablet and warm alkaline hydrogen peroxide solutions .

Recognition and Honors 🎖️

For his remarkable contributions, Professor Urakov has been awarded the Order of the Badge of Honor and holds the prestigious title of Honored Inventor of the Russian Federation . His work continues to influence and inspire the medical community globally.

Research and Innovations🔬 :

Professor Urakov invented the floating tablet and discovered warm alkaline hydrogen peroxide solutions (WAHPSs), which include new drug subgroups like bruise bleaches, pus-dissolving drugs (pyolytics), and oxygen-producing antihypoxants. These innovations offer alternatives to ECMO for hypoxemia in COVID-19 asphyxia.

🎓Publication 

Comment: Balanced Salt Solutions for Critically Ill Patients: Nonplused and Back to Basics

Thermal imaging of local skin temperature as part of quality and safety assessment of injectable drugs

    • Authors :Urakov, A., Urakova, N., Samorodov, A., … Suntsova, D., Muhutdinov, N..
    • Journal   :Heliyon
    • Year       : 2024

Understanding burn injuries in children – A step toward prevention and prompt first aid

  • Authors  :Urakov, A.L., Suntsova, D.O., Yagudin, I.I.
  • Journal    :Burns
  • Year         :  2023

ASSESSMENT OF FETAL RESISTANCE TO HYPOXIA USING THE STANGE TEST AS AN ADJUNCT TO APGAR SCALE ASSESSMENT OF NEONATAL HEALTH STATUS

  • Authors  :Shabanov, P.D., Urakov, A.L., Urakova, N.A.
  • Journal   :Medicinskij Akademiceskij Zurnal,
  • Year        :   2023

Prospects for the pharmacological validation of the use of platelets as a “peripheral model” of neurons

Assoc Prof Dr.Guanyu Chen|Drug Delivery Systems | Best Researcher Award

Published on by Top Pharmaceutical

Assoc Prof Dr.Guanyu Chen, Drug Delivery Systems,Best Researcher Award

Assoc Prof Dr.Guanyu Chen, at Sun Yat-Sen University School of Pharmaceutical Sciences Shenzhen,China

PROFILE  

scopus

🧪 Research Focus :

Associate Prof. Guanyu Chen is an expert in Drug Delivery and Immunochemotherapy at the School of Pharmaceutical Sciences, Sun Yat-sen University.

🎓 Education and Professional Experience :

He earned his Bachelor’s (2005-2008), Master’s (2009-2012), and PhD (2012-2016) degrees from the University of Auckland, New Zealand. Following his PhD, he worked as a Postdoctoral Fellow at the same university from 2017 to 2019. During this time, he also served as a Research Assistant at Ancare Scientific Ltd, Douglas Ltd, Alleva Animal Health Ltd, and Kimberly Clack Ltd. In 2019, he joined Sun Yat-sen University, China, as an Associate Professor.

💰 Research Funding :

Prof. Chen has received significant funding for his research, including the National Natural Science Foundation of China in 2022 (82273871), the Guangdong Basic and Applied Basic Research Foundation in 2021 (2021A1515110006), the Shenzhen Science and Technology Program in 2020 (GXWD20201231165807008), the 67th Batch Postdoc Research Foundation of China in 2019 (2020M673030), and the Kimberly Clarks Pharmaceutics Research Fund, USA in 2016 (32715.001).

🏅 Patents and Awards :

His achievements include two national invention patents and several prestigious awards: Overseas Senior Talent of Shenzhen, Recruiting Outstanding Overseas Talent of Guangdong, Maurice and Phyllis Paykel Research Award, Academic Career Exploration Scholarship, Edna and Denis Moloney Scholarship, FMHS-PGSA Award from the University of Auckland, Elite Editing Thesis Write-up Scholarship from Australia, and The University of Auckland Partnership Appeal Award.

📚 Editorial Roles :

Prof. Chen contributes to the academic community as a Youth Editorial Board Member for Acta Materia Medica and the Journal of Drug Delivery and Translational Research. He also serves as a Guest Editor for the Journal of Current Drug Delivery and Pharmaceutics.

🔍 Conclusion

Associate Prof. Guanyu Chen stands out as a leading researcher in drug delivery and immunochemotherapy, with a robust academic background and extensive experience. His significant contributions to the field are supported by notable research funding and a series of prestigious awards. As a dedicated academic and editorial contributor, Prof. Chen continues to advance pharmaceutical sciences through his research, mentorship, and publication efforts.

🎓Publication 

The scaffold protein AXIN1: gene ontology, signal network, and physiological function

Minocycline prevents photoreceptor degeneration in Retinitis pigmentosa through modulating mitochondrial homeostasis

Cryo-Milled β-Glucan Nanoparticles for Oral Drug Delivery

  • Authors  :Chen, G., Liu, Y., Svirskis, D., … Lu, W., Wen, J.
  • Journal    :Pharmaceutics
  • Year         :  2024

Fish oil-based microemulsion can efficiently deliver oral peptide blocking PD-1/PD-L1 and simultaneously induce ferroptosis for cancer immunotherapy

Development of a novel peptide targeting GPR81 to suppress adipocyte-mediated tumor progression

  • Authors  :Chen, S., Zhou, X., Li, W., … Liu, J., Gao, Y.
  • Journal   :Biochemical Pharmacology
  • Year        :  2023